SRPRA

Signal recognition particle receptor subunit alpha · P08240 · SRPRA on Sugi Atlas →

0 patent compounds predicted against SRPRA, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SRPRA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors PHASE1COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN
Immune Checkpoints in Predicting Response to Neoadjuvant Therapy in Rectal Cancer nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy nanRECRUITING
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Patient's Derived Organoids for Drug Screening in Glioblastoma nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
BAFF Levels and Lupus Nephritis (LN) nanWITHDRAWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SRPRA binder may also engage these)

ProteinNameSimilarity
Q9DBG7 1.000 Q9DBG7 →
Q3MHE8 1.000 Q3MHE8 →
P06625 1.000 P06625 →
Q9U5L1 0.999 Q9U5L1 →
O43032 0.992 O43032 →
Q6C3L4 0.992 Q6C3L4 →
Q54ZR7 0.991 Q54ZR7 →
Q8RXN5 0.991 Q8RXN5 →
O54774 0.991 O54774 →
Q07205 0.990 Q07205 →
Q7SH49 0.990 Q7SH49 →
Q09689 0.990 Q09689 →
P43125 0.990 P43125 →
A5E3K3 0.990 A5E3K3 →
P38431 0.990 P38431 →
B2B1M4 0.990 B2B1M4 →
P93042 0.990 P93042 →
Q9HCN4 0.990 Q9HCN4 →
DHX29 ATP-dependent RNA helicase DHX29 0.990 landscape →
P0CR92 0.989 P0CR92 →
Q6CK32 0.989 Q6CK32 →
Q6CUA5 0.989 Q6CUA5 →
Q9VXK6 0.989 Q9VXK6 →
Q22918 0.989 Q22918 →
KDM5B Lysine-specific demethylase 5B 0.989 landscape →
O00874 0.989 O00874 →
Q7PZD5 0.989 Q7PZD5 →
O94489 0.989 O94489 →
O14134 0.989 O14134 →
P0C7N6 0.989 P0C7N6 →